X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
P-BCMA-ALLO1 is a Phase 1 investigational novel BCMA-targeted allogeneic CAR-T product candidate, targeting B-cell maturation antigen (BCMA) for the treatment of relapsed/refractory multiple myeloma.
Lead Product(s): P-BCMA-ALLO1,Rimiducid
Therapeutic Area: Oncology Product Name: P-BCMA-ALLO1
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2024
Details:
Under the agreement, Astellas gains a right of exclusive negotiation and first refusal to license one of Poseida's clinical stage programs, P-MUC1C-ALLO1, an allogeneic CAR-T cell therapy in development for multiple solid tumor indications.
Lead Product(s): P-MUC1C-ALLO1,Rimiducid
Therapeutic Area: Oncology Product Name: P-MUC1C-ALLO1
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 07, 2023
Details:
BPX-601 incorporates high-performance GoCAR-T™ technology designed to target and treat solid tumors expressing prostate stem cell antigen (PSCA). It is being discontinued following the company’s assessment of BPX-601 risk/benefit profile in combination with rimiducid.
Lead Product(s): BPX-601,Rimiducid
Therapeutic Area: Oncology Product Name: BPX-601
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
BPX-601 is our first clinical candidate incorporating our high-performance GoCAR-T™ technology designed to target and treat solid tumors expressing prostate stem cell antigen (PSCA).
Lead Product(s): BPX-601,Rimiducid
Therapeutic Area: Oncology Product Name: BPX-601
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
Under the agreement with Poseida, Roche to develop allogeneic CAR-T cell therapies for hematologic malignancies, including P-BCMA-ALLO1, an allogeneic CAR-T cell product to treat multiple myeloma, and P-CD19CD20-ALLO1 to treat B cell malignancies.
Lead Product(s): P-BCMA-ALLO1,Rimiducid
Therapeutic Area: Oncology Product Name: P-BCMA-ALLO1
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $6,220.0 million Upfront Cash: $110.0 million
Deal Type: Collaboration August 03, 2022
Details:
The Phase 1 trial is an open label, multi-center, 3+3 dose-escalating study designed to assess the safety of P-PSMA-101 in up to 60 adult subjects with mCRPC. The primary objectives of this study are to determine the safety, efficacy, and maximum tolerated dose of P-PSMA-101.
Lead Product(s): P-PSMA-101,Rimiducid
Therapeutic Area: Oncology Product Name: P-PSMA-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2022
Details:
Proceeds from the financing will be used to support ongoing clinical development of BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms.
Lead Product(s): BPX-601,Rimiducid
Therapeutic Area: Oncology Product Name: BPX-601
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: MTS Securities
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 06, 2021
Details:
Under this agreement, MD Anderson will have the option to incorporate CaspaCIDe into certain cellular therapy programs. The CaspaCIDe switch consists of the CID-binding domain coupled to the signaling domain of caspase-9, an enzyme that is part of the apoptotic pathway.
Lead Product(s): Cellular Therapy,Inducible Caspase-9,Rimiducid
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center
Deal Size: Undisclosed Upfront Cash: $5.0 million
Deal Type: Licensing Agreement September 01, 2021
Details:
P-PSMA-101 is a High-Tscm Autologous CAR-T Targeting PSMA Producing Exceptionally Deep and Durable Responses in Castration-Resistant Metastatic Prostate Cancer.
Lead Product(s): P-PSMA-101,Rimiducid
Therapeutic Area: Oncology Product Name: P-PSMA-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2021
Details:
BPX-603 is Bellicum’s first dual switch GoCAR-T product candidate that incorporates the company’s iMC activation and CaspaCIDe safety switch technologies. Phase 1/2 trial will investigate the safety, tolerability, and clinical activity of BPX-603, administered with rimiducid.
Lead Product(s): BPX-603,Rimiducid
Therapeutic Area: Oncology Product Name: BPX-603
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2020
Details:
The FDA is taking this action due to the death of a pancreatic cancer patient in the trial reported to the agency by the company. The clinical investigator and Bellicum classified the patient death as unrelated to BPX-601 and rimiducid.
Lead Product(s): BPX-601,Rimiducid
Therapeutic Area: Oncology Product Name: BPX-601
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2020
Details:
U.S. FDA has lifted clinical hold on Poseida's Phase 1 study of P-PSMA-101 in metastatic castration-resistant prostate cancer and plans to resume the trial immediately. P-PSMA-101 is an autologous CAR-T therapeutic candidate in metastatic castration-resistant prostate cancer.
Lead Product(s): P-PSMA-101,Rimiducid
Therapeutic Area: Oncology Product Name: P-PSMA-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
Details:
Findings from the first four patients treated with BPX-601 followed by repeat rimiducid dosing showed evidence of rimiducid-mediated CAR-T cell activation. Clinically meaningful efficacy as measured by RECIST criteria was not observed.
Lead Product(s): BPX-601,Rimiducid
Therapeutic Area: Oncology Product Name: BPX-601
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
Bellicum is currently involved in 12 active studies, including a phase 1/2 trial of BPX-601 CAR-T cells in advanced solid tumors that express high levels of PSCA.
Lead Product(s): BPX-601,Rimiducid
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2020
Details:
A cohort treated with BPX-601 and a single dose of rimiducid showed immunomodulation in both the periphery and tumor microenvironment.
Lead Product(s): BPX-601,Rimiducid
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
